Literature DB >> 19590934

Comparison of existing disease activity indices in the follow-up of patients with Behçet's disease.

Farhad Shahram1, Alireza Khabbazi, Abdolhadi Nadji, Naghmeh Ziaie, Arash Tehrani Banihashemi, Fereydoun Davatchi.   

Abstract

The objective of this study was to determine the concordance between the Iranian Behçet's disease dynamic activity measure (IBDDAM) or the Behçet's disease current activity form (BDCAF) and expert physician global assessment (PGA) in the evaluation of disease activity changes in Behçet's disease (BD). In a prospective study, 117 consecutive patients with BD were evaluated in their two consecutive follow-up visits by IBDDAM and BDCAF. The change in disease activity was determined (increased, unchanged or decreased) according to the PGA. We used receiver operating characteristic (ROC) curve to determine an appropriate cutoff point for disease activity change. Comparison was made by Stata and kappa analysis. Comparing the area under the ROC curve showed a significant difference between IBDDAM and BDCAF (p < 0.03). The difference was more significant between nonocular IBDDAM and BDCAF (p < 0.002). Better concordance was also observed for IBDDAM (nonocular and total) with PGA than BDCAF. The difference was not significant for ocular IBDDAM. The best cutoff point for nonocular IBDDAM was 0.45, for ocular IBDDAM was 3.5, and for BDCAF was 1 point. IBDDAM was the preferred method for the evaluation of disease activity change in patients with BD (without ocular involvement) considering a change of at least 0.45.

Entities:  

Mesh:

Year:  2009        PMID: 19590934     DOI: 10.1007/s10165-009-0191-z

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  12 in total

1.  Rheumatology training and research in Iran.

Authors:  Alireza Khabbazi; Mohsen Soroosh
Journal:  Rheumatol Int       Date:  2019-05-20       Impact factor: 2.631

2.  Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.

Authors:  Hadise Kavandi; Alireza Khabbazi; Sousan Kolahi; Mehrzad Hajialilo; Farid Karkon Shayan; Mohammad Oliaei
Journal:  Clin Rheumatol       Date:  2016-05-27       Impact factor: 2.980

Review 3.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

4.  Validity and reliability of the Persian version of Behçet's disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation.

Authors:  Mahdi Vojdanian; Seyedeh Tahereh Faezi; Alan Tennant; Ann W Morgan; Pedram Paragomi; Mostafa Qorbani; Maryam Mattaji; Fereydoun Davatchi
Journal:  Rheumatol Int       Date:  2014-09-13       Impact factor: 2.631

5.  Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.

Authors:  Fariba Ghassemi; Sohrab Afshari Mirak; Hormoz Chams; Siamak Sabour; Mehdi Nilli Ahmadabadi; Fereidoun Davatchi; Farhad Shahram
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

6.  Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet's disease.

Authors:  Ahmet Omma; Sevinc Can Sandikci; Seda Colak; Duygu Tecer; Cigdem Yucel; Zeynep Ozbalkan
Journal:  Postepy Dermatol Alergol       Date:  2018-11-13       Impact factor: 1.837

7.  The expression and methylation status of vitamin D receptor gene in Behcet's disease.

Authors:  Sam Seydi Shirvani; Mohammad Nouri; Ebrahim Sakhinia; Zohreh Babaloo; Golamreza Jadideslam; Alipour Shahriar; Jafar Farhadi; Alireza Khabbazi
Journal:  Immun Inflamm Dis       Date:  2019-12

8.  Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.

Authors:  Dae-Jun Kim; Seung-Ye Baek; Mi-Kyung Park; Kyung-Su Park; Jae Ho Lee; Sung-Hwan Park; Ho-Youn Kim; Seung-Ki Kwok
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

9.  Efficacy of Nigella sativa seeds oil in patients with Behcet's disease: a double-blind randomized controlled trial.

Authors:  Hadiseh Kavandi; Mehrzad Hajialilo; Alireza Khabbazi
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec

10.  Correlation of clinical signs and symptoms of Behçet's disease with mean platelet volume (MPV) and red cell distribution width (RDW).

Authors:  Maryam Masoumi; Soraya Shadmanfar; Fereydoun Davatchi; Farhad Shahram; Massoomeh Akhlagi; Tahereh Faezi; Hoda Kavosi; Soroush Moradi; Javad Balasi
Journal:  Orphanet J Rare Dis       Date:  2020-10-21       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.